HIV

Understanding what constitutes a 'good' immune response to HIV may provide important information for vaccine design and intervention.

This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.

On August 30, 2018, the FDA approved Merck’s doravirine (Pifeltro) a non-nucleoside reverse transcriptase inhibitor and doravirine/lamivudine/tenofovir (Delstrigo) a once-daily single tablet regimen for the treatment of HIV-1 infection in appropriate patients.

Kaposi sarcoma is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels, and most commonly affects individuals with HIV.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

Results of the recent study, published in The Lancet, support the benefits of early testing and treatment for HIV, as well as the message of Prevention Access Campaign’s U=U (undetectable equals untransmittable) initiative.

"If successful, this has the potential to contribute to a cure for HIV."

Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.

Top news of the day from across the health care landscape.

In rare cases, patients with HIV can experience a paradoxical response to antiretroviral therapy known as extreme immune decline.

Study shows the importance of screening and treatment for depression, especially among patients with HIV since there has been an increase in life expectancy due to antiretroviral therapy.

Top news of the week from Specialty Pharmacy Times.

With this approval, patients who have never been treated have the option of a 2-drug regimen in a single tablet, as opposed to the standard-of-care 3-drug regimen for HIV.

With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.

For the study, the researchers assessed whether a slow-release, long-acting, implantable naltrexone could improve outcomes for patients with HIV and opioid addiction.

An implantable form of naltrexone was more effective in improving HIV outcomes in patients compared with oral naltrexone.

HIV infection is associated with higher rates of hepatitis C replication.

The IAVI WOO1 study is one of the first clinical trials of a native-like Env trimer and the first time that this particular trimer is being evaluated in humans

The goals are to assess the candidate’s safety and to determine if the vaccination induces the human immune system to produce proteins called neutralizing antibodies.

An updated transmission model indicates that most new HIV infections occur due to a lack of diagnosis and treatment.

Study finds patients with negative beliefs about medications may be more likely to experience adverse effects when taking antiretroviral therapy.

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

A recently presented study indicates that while overall HIV mortality is declining, the rate of opioid overdose deaths in HIV patients is increasing.

Data compiled from a recent study show that this therapy was highly effective in preventing SHIV infection in a macaque model mimicking vaginal transmission of the virus.

Top news of the day from across the health care industry.

If approved, rilpivirine plus cabotegravir would be the first monthly dosing option for adult patients with HIV.

Recently approved by the US Food and Drug Administration (FDA), the Biktarvyregimen is indicated for the treatment of adults with HIV-1 who have no history of antiretroviral therapy.

An individual treated for HIV is believed to be in long-term remission, according to experts in the United Kingdom. 'The London Patient’ is only the second documented case of sustained remission for HIV infection.

Top news of the day from across the health care landscape.

Many women are unaware of HIV pre-exposure prophylaxis (PrEP) but show a keen interest in spreading the word once they learn about the option, according a recent study in the journal Contraception.